2019
DOI: 10.1182/bloodadvances.2018026211
|View full text |Cite
|
Sign up to set email alerts
|

Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia

Abstract: Inotuzumab ozogamicin (InO) is a recently US Food and Drug Administration–approved antibody–drug conjugate for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). InO consists of a CD22-targeting immunoglobulin G4 humanized monoclonal antibody conjugated to calicheamicin. Although initially developed for the treatment of non-Hodgkin lymphoma (NHL) because of activity in preclinical models and high response rates in indolent lymphomas, a phase 3 trial was negative and further develop… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
27
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 46 publications
(27 citation statements)
references
References 46 publications
0
27
0
Order By: Relevance
“…[33]. Calicheamicin has been used in inotuzumab ozogamicin and gemtuzumab ozogamycin [11,[34][35][36].…”
Section: Characteristics Of Payloadsmentioning
confidence: 99%
“…[33]. Calicheamicin has been used in inotuzumab ozogamicin and gemtuzumab ozogamycin [11,[34][35][36].…”
Section: Characteristics Of Payloadsmentioning
confidence: 99%
“…However, while these drugs exert significant therapeutic effects, their activity is still limited, among others due to resistance mechanisms, which are for example associated with the modulation of their target antigens [23]. Downmodulation of target antigens associated with failure of therapy has been reported for approaches comprising binders of CD19 like the BiTE Blinatumomab and also anti-CD19 CAR-T cells [24,25] as well as the CD22-targeting ADC Inotuzumab ozogamicin [26][27][28]. With our FLT3 binder 4G8, we also observed downmodulation of FLT3 expression on AML and B-ALL cells [12], but even high mAb concentrations did not reduce antigen expression by more than 30%-40%.…”
Section: Discussionmentioning
confidence: 99%
“…This linker connecting the antibody to calicheamicin forms a hydrazone with the hydrazide of the calicheamicin derivative, which is hydrolysed in lysosomal pH, and calicheamicin is released, leading to cell death. However, the acid-sensitive linker has a low plasma stability of 48–72 h [ 56 , 57 , 58 ]. The protease-cleavable linker, e.g., dipeptide valine-citrulline (Val-Cit, V-C), is utilized in brentuximab vedotin to link the monomethylauristatin E (MMAE) payload to the anti-CD30 antibody.…”
Section: Design and Structure Of Antibody–drug Conjugatesmentioning
confidence: 99%
“…Inotuzumab ozogamicin (Besponsa) is an ADC composed of anti-CD22 monoclonal antibody linked to a semi-synthetic derivative of calicheamicin Calich-DMH. Calicheamicin is a DNA-damaging cytotoxic agent derived from soil bacterium Micromonospora echinospora [ 58 ].…”
Section: Clinically Approved Adcsmentioning
confidence: 99%